Head and Neck (September 2017): Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a 71 year old male with a history of  T1N0M0 glottic laryngeal cancer diagnosed in 2005 and treated with radiation.He did well until 2010 when he developed a T2 supraglottic laryngeal cancer, thought to represent a 2nd primary tumor, and underwent laryngectomy with neck dissection and tracheostomy with four positive lymph nodes and no ECE .  In 2015, he developed a T1 p16 negative squamous cell carcinoma of the right tongue base that was treated with robotic resection with achievement of negative surgical margins

Originally posted on a forum in the ASCO Connection, users now have the opportunity to claim CME, completion, or participation certificates for completing this activity.

Learning Objectives

  • Explain the recent changes in the management of patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
  • Describe the role of NGS in the management of patients with R/M HNSCC
  • Explain the extent and type of mutations in the PI3K pathway in HPV positive and HPV negative HNSCC
  • Describe the emerging information on the clinical utility of targeting PIK3CA mutations in patients with R/M HNSCC

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits™
  • ABIM MOC Points
  • CNE Contact Hours
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Note: This course expires on September 27, 2020. Participants must complete all necessary course components by this date to receive credit.